The news of two high-value distribution deals in China caused Bon Natural Life Limited’s (NASDAQ: BON) stock to jump sharply. The shares of BON surged 51.36% to $2.12 as of the latest trading session. This sharp increase follows new alliances meant to increase the company’s presence in the market for functional health goods.
Strategic Sales Agreement to Boost Tea Pigment Products
Bon Natural Life recently entered a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd., a prominent distributor of functional ingredients in China. The agreement, valued at USD 24 million over a 24-month term, grants Shanghai Risesun the rights to market and distribute BON’s tea pigment series health products across China.
Tea pigments—known for their lipid-lowering, glycemic-regulating, antioxidant, and anti-ulcer properties—are gaining momentum in the functional food and supplement sectors.
Positioned as a natural progression from tea polyphenols, these ingredients show particular promise in the areas of digestive health and blood glucose management. Supported by a steady supply of tea raw materials and increasing global tea consumption, Bon’s product line is well-aligned with consumer trends and industry growth.
Exclusive Partnership to Advance Blood Sugar Solutions
In a separate but complementary development, Bon Natural Life also signed an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd. Beijing Huahai Keyuan is designated as the sole distributor for BON’s postbiotic hypoglycemic component under this 36-month agreement, which is valued at USD 32 million.
This patented formulation is engineered to regulate postprandial blood sugar spikes with high efficacy, safety, and ease of integration into daily routines—critical features that support user adherence and market appeal.
Growth Trajectory and Market Positioning
As it looks to maintain its position as the industry leader in functional health, these partnerships represent a turning point for Bon Natural Life. BON hopes to increase shareholder value, boost revenue growth, and maybe enter a market worth more than $1 billion by utilizing creative bioactive goods and strategic distribution networks. These tactical partnerships highlight BON’s dedication to globally impactful, scalable, health-driven solutions.
